U.S. database may show difference in risk rates between anti-VEGFs

LONDON — Significantly fewer endophthalmitis events were associated with ranibizumab injections than aflibercept injections among patients with wet age-related macular degeneration, according to a presentation here.The findings of “real-world” endophthalmitis rates between the two licensed treatments for wet AMD “underline the importance of real-world, post-market approval of observational monitoring of novel medicines,” authors Simon P. Kelly and colleagues wrote in a poster presented at the Euretina Congress.